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Study 1. The Cytotoxicity of Bupivcaine, Ropivacaine, and Mepivacaine on Human Chondrocytes and
Cartilage. Breu et al.
Objective: To assess the chondrotoxic effects of mepivacaine, ropivacaine, and bupivacaine.
Conclusion: Local anesthetic chondrotoxicity increases with drug type and concentration from
ropivacaine to bupivacaine.
Study Critique: In vitro study performed with a small non specified sample size, location of articular
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In 40 to 65 year olds with osteoarthritic joint pain, what are the toxic effects of
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Study  2.  Apoptosis  and  Mitochondrial  Dysfunction  in  Human  Chondrocytes  Following  Exposure  to  
Lidocaine,  Bupivacaine,  and  Ropivacaine.  Grishko,  PhD  et  al.
Objective:  To  investigate  the  effects  of  lidocaine,  bupivacaine,  and  ropivacaine  on  human  
chondrocyte  viability  and  mitochondrial  function  in  vitro  and  to  characterize  the  type  of  cell  death  
elicited  following  exposure.
Conclusion:  Bupivacaine  and  ropivacaine  are  chondrotoxic  to  human  cartilage  through  the  induction  
of  cell  apoptosis.
Study  Critique:  In  vitro  study  performed  with  a  small  non  specified  sample  size.
Study  3.  Comparison  of  Ropivacaine  and  Bupivacaine  Toxicity  in  Human  Articular  Cartilage.  Piper  et  
al.
Objective:  To  determine  whether  0.5%  bupivacaine is  chondrotoxic  to  human  articular  cartilage  and  
whether  0.5%  ropivacaine  is  a  less  toxic  alternative.
Conclusion:  0.5%  bupivacaine  is  more  chondrotoxic  than  0.5%  ropivacaine.
Study  Critique:  In  vitro  study  performed  with  a  small  non  specified  sample  size,  intact  cartilage  
samples  were  used,  only  measured  the  effects  of  one  concentration  and  at  only  one  time  interval,  and  
used  obscured  data  in  tables.
Breu,	  et	  al.	  (Study	  1) Grishko,	  et	  al.	  (Study	  2) Piper,	  et	  al.	  (Study	  3)






42-­‐62	  year	  olds 53	  +/-­‐ 16	  years	  old N/A
OA	  or	  intact	  
cartilage
OA OA Intact
Bone	  used N/A Femoral	  condyles	  and	  tibial	  
plataeus
3	  from	  femoral	  head
2	  from	  tibial	  plateau
Drug	  
concentrations
1	  mL	  Bupivacaine	  0.03125%,	  
0.0625%,	  0.125%,	  0.25%,	  0.5%
1	  mL	  Ropivacaine	  0.03125%,	  




200	  µL	  0.5%	  Bupivacaine
200	  µL	  0.5%	  Ropivacaine
Exposure	  Time 1	  hour 1	  hour 30	  minutes
Control Saline Saline Saline
Statistical	  
Significance
P	  <	  0.01 P	  <	  0.05 P	  <	  0.05
Flow	  Cytometry At	  24	  hours	  and	  96	  hours:
• Concentrations	  <	  0.75%	  
ropivacaine	  and	  0.25%	  
bupivacaine	  showed	  no	  
cytotoxic	  effects
• 0.75%	  ropivacaine	  >	  0.5%	  
bupivacaine	  in	  cell	  viability
• Significant	  cytotoxicity	  seen	  
after	  24	  and	  96	  hours	  with	  
bupivacaine	  and	  96	  hours	  with	  
ropivacaine
At	  24	  hours:
• Detectable	  but	  not	  significant	  
decrease	  in	  cell	  viability	  with	  
0.5%	  bupivacaine	  
• No	  decrease	  with	  0.25%	  
bupivacaine	  and	  0.5%	  and	  0.2%	  
ropivacaine
At	  120	  hours:
• Only	  0.2%	  ropivacaine	  did	  not	  






• Bupivacaine	  >	  ropivacaine	  in	  
chondrotoxicity
• Cell	  viability	  was	  higher	  in	  
equipotent	  concentrations	  of	  
ropivacaine	  vs.	  bupivacaine
N/A At	  24	  hours:
• 0.5%	  ropivacaine	  >	  0.5%	  
bupivacaine	  in	  cell	  viability
• No	  significant	  difference	  in	  
viability	  b/w	  ropivacaine	  and	  
normal	  saline
Caspase	  activity 0.5%	  bupivacaine	  >	  0.75%	  
ropivacaine	  in	  cell	  apoptotic	  
fragments
Increase	  in	  caspase	  3	  and	  caspase	  






N/A N/A At	  24	  hours:
• 0.5%	  ropivacaine	  >	  0.5%	  
bupicacaine	  in	  cell	  viability
• Normal	  saline	  >	  bupivacaine	  and	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Figure 1. Dose-­response curves of different concentrations of bupivacaine and ropivacaine.
Chondrocyte apoptosis (A) and necrosis (N) were measured using flow cytometry at a time
interval of 96 hours after a 1-­hour exposure. Significant chondrotoxicity is seen with 0.5%
bupivacaine and 0.75% ropivacaine, increasing from ropivacaine to bupivacaine.
Intraarticular injections of corticosteroids used in combination with local
anesthetics are a commonly practiced therapy for osteoarthritis. Injections of
corticosteroids and local anesthetics can alleviate pain and inflammation in an
osteoarthritic joint. Bupivacaine is currently the most commonly used
intraarticular local anesthetic due to its long duration of action. Recent
experimental studies have suggested that bupivacaine may be toxic to articular
cartilage. Ropivacaine, a newer local anesthetic agent, may be a promising
alternative to bupivacaine for intraarticular injections.
Due to a current lack of definitive data, this review aims to compare
experimental studies on the toxic effects of bupivacaine and ropivacaine on
chondrocytes. Studies compared these two drugs in order to determine the best
local anesthetic agent, the dose of that agent, and duration that would be least
harmful to articular cartilage.
CLINICAL SCENARIO:
Mrs. OA is a 52 year old woman suffering from osteoarthritis of her right
knee. The pain is described as constant and worsening. She has attempted
weight loss, activity modifications, nonsteroidal anti-­inflammatory drugs,
acetaminophen, and topical analgesics but has experienced no relief of
symptoms. The orthopedist discusses combined corticosteroid and anesthetic
intraarticular injections with Mrs. OA as a next step option. The orthopedist
recently heard about potential toxic effects of local anesthetics on
chondrocytes. He wants to know which anesthetic and concentration has the
least chondrotoxic effects in order to prevent further damage to Mrs. OA's knee.
In conclusion, all three studies revealed that both ropivacaine and
bupivacaine are toxic to chondrocytes in a time dependent, drug dependent, and
concentration dependent manner. The collective results show that concentrations
less than 0.75% ropivacaine and concentrations of 0.25% bupivacaine or less
have fewer chondrotoxic effects on osteoarthritic cartilage. These results further
indicate that chondrotoxicity increases from ropivacaine to bupivacaine.
FUTURE STUDIES:
In order to further define the clinical relevance of these findings, an in vivo
experiment would be necessary in order to observe the toxic effects of
bupivacaine and ropivacaine on human articular cartilage directly and to better
represent the pharmacokinetics of the agents. Future studies should also focus
on comparing several equipotent concentrations of ropivacaine and bupivacaine
and measuring the effects for longer durations.
CLINICAL APPLICATION:
The clinical impact of these results remains unclear. In regards to our clinical
scenario, the results of these studies have failed to answer the question: which
local anesthetic agent and concentration is the least toxic to chondrocytes? The
results did however demonstrate that certain thresholds of both ropivacaine and
bupivacaine show statistically significant toxic effects to chondrocytes. This is an
important revelation that clinicians should be wary of when choosing an anesthetic
and which concentration to use. We recommend that orthopedists should use the
lowest possible concentration of bupivacaine or ropivacaine to reach therapeutic
levels until further studies are performed.
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